Inverse lichenoid drug eruption associated with nivolumab

JAAD Case Reports

Volumn 3, Issue 1, 2017, Pages 7-9

  Guggina, Lauren M ^a   Yanes, Daniel A ^a   Choi, Jennifer N ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

anti programmed cell death 1; drug reaction; immune reaction; immunotherapy; lichenoid reaction; nivolumab; programmed cell death protein 1

Indexed keywords

ANTIPRURITIC AGENT; CLOBETASOL; LIDOCAINE; NIVOLUMAB; NYSTATIN;

ACANTHOSIS; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CASE REPORT; CLITORIS; CONSTIPATION; CREAM; DRUG ERUPTION; DRUG TREATMENT FAILURE; DYSURIA; FEMALE; GENERAL CONDITION DETERIORATION; HUMAN; HUMAN TISSUE; INGUINAL REGION; INVERSE LICHENOID DRUG ERUPTION; KIDNEY METASTASIS; LICHENOID ERUPTION; OINTMENT; PAPULE; PERINEUM; PRIORITY JOURNAL; PUNCH BIOPSY; SKIN BIOPSY; SKIN EXAMINATION; TOPICAL TREATMENT; URINARY FREQUENCY; VITILIGO; VULVA PRURITUS;

EID: 85007238116     PISSN: None     EISSN: 23525126     Source Type: Journal    
DOI: 10.1016/j.jdcr.2016.11.002     Document Type: Article

References (7)

1. 1 Ott, P.A., Hodi, F.S., Robert, C., CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 19:19 (2013), 5300–5309.
2. 2 Hofmann, L., Forschner, A., Loquai, C., et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 60 (2016), 190–209.
3. 3 Topalian, S.L., Sznol, M., McDermott, D.F., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:10 (2014), 1020–1030.
4. 4 Hwang, S.J., Carlos, G., Wakade, D., et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. J Am Acad Dermatol 74:3 (2016), 455–461.e1.
5. 5 Totonchy, M.B., Ezaldein, H.H., Ko, C.J., Choi, J.N., Inverse Psoriasiform Eruption During Pembrolizumab Therapy for Metastatic Melanoma. JAMA Dermatol 152:5 (2016), 590–592.
6. 6 Joseph, R.W., Cappel, M., Goedjen, B., et al. Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy. Cancer Immunol Res 3:1 (2015), 18–22.
7. 7 Sanlorenzo, M., Vujic, I., Daud, A., et al. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. JAMA Dermatol 151:11 (2015), 1206–1212.